Total Funding
5
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
-9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
350066
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Randi Kronthal-Sacco: Executive Vice President, Commercial OperationsPast Role: Johnson & Johnson, Senior Executive
Guy Miller: Chairman, CEO & Co-FounderPast Role: Galileo Pharmaceuticals, Chairman and CEO
About the Company
Edison is a world leader in the discovery and development of redox drugs. The company has obtained orphan designation in both the United States and Europe for its first drug candidate, EPI-743 . Vincerinone is now in phase 2 clinical development. It is being evaluated in multiple clinical indications where defects in the mitochondrial proteins and
redox control have been well characterized.
